HRP20170386T1 - Stabilizacija fsh - Google Patents

Stabilizacija fsh Download PDF

Info

Publication number
HRP20170386T1
HRP20170386T1 HRP20170386TT HRP20170386T HRP20170386T1 HR P20170386 T1 HRP20170386 T1 HR P20170386T1 HR P20170386T T HRP20170386T T HR P20170386TT HR P20170386 T HRP20170386 T HR P20170386T HR P20170386 T1 HRP20170386 T1 HR P20170386T1
Authority
HR
Croatia
Prior art keywords
formulation
fsh
use according
salt
amount
Prior art date
Application number
HRP20170386TT
Other languages
English (en)
Croatian (hr)
Inventor
Helen Ulrika Sjögren
Heidi Louise Bagger
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of HRP20170386T1 publication Critical patent/HRP20170386T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Fats And Perfumes (AREA)
HRP20170386TT 2010-07-30 2011-07-28 Stabilizacija fsh HRP20170386T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10171428A EP2417982A1 (en) 2010-07-30 2010-07-30 Stabilization of gonadotropins
EP11736111.3A EP2598160B1 (en) 2010-07-30 2011-07-28 Stabilization of fsh
PCT/EP2011/062986 WO2012013742A2 (en) 2010-07-30 2011-07-28 Stabilization of fsh

Publications (1)

Publication Number Publication Date
HRP20170386T1 true HRP20170386T1 (hr) 2017-05-05

Family

ID=43216624

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20170386TT HRP20170386T1 (hr) 2010-07-30 2011-07-28 Stabilizacija fsh

Country Status (27)

Country Link
US (3) US8993732B2 (enExample)
EP (3) EP2417982A1 (enExample)
JP (3) JP5860047B2 (enExample)
KR (2) KR101820115B1 (enExample)
CN (2) CN103052398B (enExample)
AR (1) AR082776A1 (enExample)
AU (1) AU2011284702C1 (enExample)
BR (1) BR112013002312B1 (enExample)
CA (1) CA2805864A1 (enExample)
DK (1) DK2598160T3 (enExample)
ES (1) ES2623634T3 (enExample)
HR (1) HRP20170386T1 (enExample)
HU (1) HUE033592T2 (enExample)
IL (2) IL223821A (enExample)
JO (1) JO3229B1 (enExample)
LT (1) LT2598160T (enExample)
MX (2) MX356951B (enExample)
NZ (2) NZ606366A (enExample)
PL (1) PL2598160T3 (enExample)
PT (1) PT2598160T (enExample)
RS (1) RS55772B1 (enExample)
RU (1) RU2574012C2 (enExample)
SA (1) SA114350786B1 (enExample)
SI (1) SI2598160T1 (enExample)
TW (1) TWI439283B (enExample)
WO (1) WO2012013742A2 (enExample)
ZA (1) ZA201209497B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2015075743A1 (en) * 2013-11-12 2015-05-28 Cadila Healthcare Limited Formulation for gonadotropins
CN105727260A (zh) * 2016-02-03 2016-07-06 华侨大学 一种卵泡刺激素的长效制剂
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
FR3083089A1 (fr) * 2018-06-29 2020-01-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
IL275148B2 (en) 2017-12-07 2025-02-01 Adocia An injectable solution with a pH of 7 comprising at least one basic insulin with a PI between 5.8 and 8.5 and a copolyamino acid bearing carboxylate charges and hydrophobic radicals.
KR20200106891A (ko) 2017-12-07 2020-09-15 아도시아 pI가 5.8 내지 8.5인 적어도 1종의 기저 인슐린, 및 카복실산염 전하 및 소수성 라디칼을 보유하는 코-폴리아미노산을 포함하는 pH 7의 주사용 용액
FR3084584B1 (fr) * 2018-08-03 2020-11-06 Adocia Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes
FR3084586B1 (fr) * 2018-08-03 2020-11-06 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes
JP7425459B2 (ja) * 2019-10-11 2024-01-31 株式会社シノテスト 安定化されたhmgb1含有溶液

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996029095A1 (en) 1995-03-21 1996-09-26 Applied Research Systems Ars Holding N.V. Hcg liquid formulations
CZ297042B6 (cs) * 1996-05-29 2006-08-16 Delsitechoy Dodávkové zarízení pro pomalé uvolnování biologicky úcinného cinidla, jeho pouzití a farmaceutický prostredek s jeho obsahem
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
PL346127A1 (en) * 1998-07-23 2002-01-28 Lilly Co Eli Fsh and fsh variant formulations, products and methods
UA89781C2 (uk) * 2004-04-07 2010-03-10 Арес Трейдінг С.А. Рідкий склад гормона росту
KR101105871B1 (ko) * 2005-09-27 2012-01-16 주식회사 엘지생명과학 인 난포자극호르몬의 안정한 용액 제형
KR101573773B1 (ko) * 2008-02-08 2015-12-02 바이오제너릭스 게엠베하 Fsh의 액체 포뮬레이션
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
CN101614748A (zh) * 2008-06-25 2009-12-30 上海新波生物技术有限公司 促卵泡激素时间分辨免疫荧光分析法及试剂盒
JP5808323B2 (ja) * 2009-06-22 2015-11-10 アムジエン・インコーポレーテツド 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング
EP2533800B1 (en) * 2010-02-12 2016-07-20 Intas Pharmaceuticals Ltd. Liquid formulation of follicle stimulating hormone
EP2417982A1 (en) * 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins

Also Published As

Publication number Publication date
IL223821A (en) 2017-01-31
US20130210727A1 (en) 2013-08-15
TWI439283B (zh) 2014-06-01
CN105106939A (zh) 2015-12-02
CA2805864A1 (en) 2012-02-02
KR20180008916A (ko) 2018-01-24
AR082776A1 (es) 2013-01-09
KR101991756B1 (ko) 2019-06-21
BR112013002312B1 (pt) 2021-09-21
MX2013000681A (es) 2013-02-27
AU2011284702B2 (en) 2015-05-14
SA114350786B1 (ar) 2015-07-09
KR101820115B1 (ko) 2018-01-18
EP2598160B1 (en) 2017-02-22
RS55772B1 (sr) 2017-07-31
WO2012013742A2 (en) 2012-02-02
JP6522711B2 (ja) 2019-05-29
JO3229B1 (ar) 2018-03-08
KR20130143692A (ko) 2013-12-31
ES2623634T3 (es) 2017-07-11
TW201208694A (en) 2012-03-01
PL2598160T3 (pl) 2017-06-30
JP2016102127A (ja) 2016-06-02
US9463221B2 (en) 2016-10-11
JP5860047B2 (ja) 2016-02-16
EP2417982A1 (en) 2012-02-15
BR112013002312A2 (pt) 2018-03-20
US20150265681A1 (en) 2015-09-24
MX356951B (es) 2018-06-21
AU2011284702C1 (en) 2015-09-03
CN103052398A (zh) 2013-04-17
WO2012013742A3 (en) 2012-04-19
EP2598160A2 (en) 2013-06-05
MX341464B (es) 2016-08-22
AU2011284702A1 (en) 2013-02-07
IL249920A0 (en) 2017-03-30
NZ606366A (en) 2014-08-29
DK2598160T3 (en) 2017-03-27
PT2598160T (pt) 2017-03-30
SI2598160T1 (sl) 2017-07-31
US20170216405A1 (en) 2017-08-03
JP2013532677A (ja) 2013-08-19
CN103052398B (zh) 2015-09-16
LT2598160T (lt) 2017-04-10
HUE033592T2 (hu) 2017-12-28
NZ628962A (en) 2016-01-29
JP2018048188A (ja) 2018-03-29
ZA201209497B (en) 2013-08-28
EP3144010A1 (en) 2017-03-22
US8993732B2 (en) 2015-03-31
RU2574012C2 (ru) 2016-01-27
RU2012157154A (ru) 2014-09-10

Similar Documents

Publication Publication Date Title
HRP20170386T1 (hr) Stabilizacija fsh
JP2013532677A5 (enExample)
MX2009013255A (es) Matriz de solidificacion que incluye una sal de un acido mono-, di- o tri-carboxilico saturado de cadena recta.
FI3810201T3 (fi) GIP/GLP1-agonistin koostumuksia
EP3437628A4 (en) COSMETIC COMPOSITION USING ALBUMINE, HYALURONIC ACID OR COLLAGEN AS AN ACTIVE IN CELL CULTURE MEDIUM
HRP20220793T1 (hr) Oftalmološki vodeni sastav
MX2017007178A (es) Formulaciones liquidas estables de virus de vacuna.
UY35859A (es) ?combinación farmacéutica que comprende amlodipina, losartán y rosuvastatina?.
PE20090951A1 (es) Suspension pediatrica estabilizada de carisbamato
RU2011108177A (ru) Ингибирующий буровой раствор
CL2014000035A1 (es) Composicion en forma de un gel para la preparacion de un producto alimenticio, que comprende agua en una cantidad de 30 a 70% en peso, saborizantes desde 1 a 40%, sal desde 10 a 25% y agentes gelificantes desde 0,15 a 12% que contienen al menos agar y xantano; y proceso para preparar dicha composicion.
AR105726A1 (es) Fluoro-inorgánicos para la acidificación o neutralización de sistemas de agua
MA32498B1 (fr) Compositions pharmaceutiques de rosuvastatine calcium
HRP20171592T1 (hr) Postupci i pripravci namijenjeni primjeni moksifloksacina u uho
HRP20191050T1 (hr) Pripravak protiv virusnog konjunktivitisa koji sadrži jota-karagenan
RU2013140665A (ru) Композиции для ухода за полостью рта
HK1220113A1 (zh) 药物软明胶胶囊剂型
FR2991178B1 (fr) Compositions topiques de type gel aqueux sous forme de suspension homogene d'un principe actif de la classe des retinoides contenant au moins une silice hydrophobe.
MX358604B (es) Composicion liquida acuosa que contiene acido 2-amino-3-(4-bromobenzoil) fenilacetico.
BR112016001779A2 (pt) comprimido em bicamada, e, processo
MX373026B (es) Composiciones antitranspirantes anhidras.
RU2007131719A (ru) Жидкое моющее средство "биолан"
FR3031514B1 (fr) Composite de sels de sodium et d'ammonium pour la depollution des fumees
AR094203A1 (es) Formulacion farmaceutica en n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida
PE20070464A1 (es) Forma farmaceutica con liberacion sostenida independiente del ph de un ingrediente activo, para ingredientes activos que tienen una solubilidad que depende en gran medida del ph